135 related articles for article (PubMed ID: 2481185)
1. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil.
Clozel JP; Banken L; Osterrieder W
J Cardiovasc Pharmacol; 1989 Nov; 14(5):713-21. PubMed ID: 2481185
[TBL] [Abstract][Full Text] [Related]
2. Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillation.
Billman GE
Eur J Pharmacol; 1992 Dec; 229(2-3):179-87. PubMed ID: 1490522
[TBL] [Abstract][Full Text] [Related]
3. The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts.
Clozel JP; Véniant M; Osterrieder W
Cardiovasc Drugs Ther; 1990 Jun; 4(3):731-6. PubMed ID: 1963792
[TBL] [Abstract][Full Text] [Related]
4. Infarct size-limiting properties of Ro 40-5967, a novel nondihydropyridine calcium channel, in anesthetized rats: comparison with verapamil.
Richard V; Tron C; Blanc T; Thuillez C
J Cardiovasc Pharmacol; 1995 Apr; 25(4):552-7. PubMed ID: 7596122
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacologic profile of Ro 40-5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action.
Osterrieder W; Holck M
J Cardiovasc Pharmacol; 1989 May; 13(5):754-9. PubMed ID: 2472524
[TBL] [Abstract][Full Text] [Related]
6. The novel calcium antagonist Ro 40-5967 limits myocardial infarct size in the dog.
Vander Heide RS; Schwartz LM; Reimer KA
Cardiovasc Res; 1994 Oct; 28(10):1526-32. PubMed ID: 8001041
[TBL] [Abstract][Full Text] [Related]
7. Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction.
Véniant M; Clozel JP; Hess P; Wolfgang R
J Cardiovasc Pharmacol; 1991 Feb; 17(2):277-84. PubMed ID: 1709233
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts.
Orito K; Satoh K; Taira N
J Cardiovasc Pharmacol; 1993 Aug; 22(2):293-9. PubMed ID: 7692172
[TBL] [Abstract][Full Text] [Related]
9. Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise.
Muller CA; Opie LH; McCarthy J; Hofmann D; Pineda CA; Peisach M
J Am Coll Cardiol; 1998 Jul; 32(1):268-74. PubMed ID: 9669280
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of calcium-channel blocking agents on left ventricular function during acute ischemia in dogs with and without congestive heart failure.
Urquhart J; Epstein SE; Patterson RE
Am J Cardiol; 1985 Jan; 55(3):10B-16B. PubMed ID: 3969856
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine.
Véniant M; Clozel JP; Hess P; Wolfgang R
J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S55-8. PubMed ID: 1725005
[TBL] [Abstract][Full Text] [Related]
12. The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation.
Billman GE; Hamlin RL
J Pharmacol Exp Ther; 1996 Jun; 277(3):1517-26. PubMed ID: 8667218
[TBL] [Abstract][Full Text] [Related]
13. Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure.
Su J; Renaud N; Carayon A; Crozatier B; Hittinger L
Br J Pharmacol; 1994 Oct; 113(2):395-402. PubMed ID: 7834190
[TBL] [Abstract][Full Text] [Related]
14. Potential-dependent inhibition of cardiac Ca2+ inward currents by Ro 40-5967 and verapamil: relation to negative inotropy.
Fang LM; Osterrieder W
Eur J Pharmacol; 1991 Apr; 196(2):205-7. PubMed ID: 1651875
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive properties of the novel calcium antagonist (1S,2S)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino] ethyl]-6- fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride in rat models of hypertension. Comparison with verapamil.
Hefti F; Clozel JP; Osterrieder W
Arzneimittelforschung; 1990 Apr; 40(4):417-21. PubMed ID: 2357242
[TBL] [Abstract][Full Text] [Related]
16. Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil.
Cremers B; Flesch M; Südkamp M; Böhm M
J Cardiovasc Pharmacol; 1997 May; 29(5):692-6. PubMed ID: 9213214
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of verapamil, diltiazem, and nifedipine on hemodynamics and left ventricular function during acute myocardial ischemia in dogs.
Urquhart J; Patterson RE; Bacharach SL; Green MV; Speir EH; Aamodt R; Epstein SE
Circulation; 1984 Feb; 69(2):382-90. PubMed ID: 6690104
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of signal Ca2+ in dog coronary arterial vascular muscle cells by Ro 40-5967.
Mishra SK; Hermsmeyer K
J Cardiovasc Pharmacol; 1994 Jul; 24(1):1-7. PubMed ID: 8078332
[TBL] [Abstract][Full Text] [Related]
19. Reduction of exercise-induced regional contractile dysfunction in dogs using a novel calcium channel blocker (Ro 40-5967).
Guth BD
Cardiovasc Drugs Ther; 1992 Apr; 6(2):167-71. PubMed ID: 1390329
[TBL] [Abstract][Full Text] [Related]
20. Effects of calcium entry blockers on coronary constriction and myocardial ischemia due to leukotriene D4.
Ezra D; Boyd LM; Goldstein RE; Feuerstein G
J Pharmacol Exp Ther; 1985 Apr; 233(1):229-34. PubMed ID: 3981457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
